Login / Signup

E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial.

Jan Philipp BewersdorfMaximilian StahlJustin TaylorXiaoli MiNamrata Sonia ChandhokJustin WattsAndriy DerkachMateusz WysockiSydney X LuJessie BourcierSimon J HoggJahan RahmanSana ChaudhryTulasigeri M TotigerOmar Abdel-WahabEytan M Stein
Published in: Leukemia (2023)
Keyphrases
  • phase ii
  • clinical trial
  • open label
  • dendritic cells
  • bone marrow
  • acute myeloid leukemia
  • phase iii
  • double blind
  • wild type
  • placebo controlled
  • study protocol
  • randomized controlled trial
  • immune response